XNAS
SPRB
Market cap3mUSD
Jul 11, Last price
0.09USD
1D
21.92%
1Q
-69.42%
IPO
-99.48%
Name
Spruce Biosciences Inc
Chart & Performance
Profile
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
Income | ||||||
Revenues | 10,089 | |||||
Cost of revenue | 111,514 | 47,712 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (101,425) | (47,712) | ||||
NOPBT Margin | ||||||
Operating Taxes | (1,103) | |||||
Tax Rate | ||||||
NOPAT | (101,425) | (46,609) | ||||
Net income | (47,919) 6.30% | (45,077) 5.60% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 53,616 | (241) | ||||
BB yield | -47.52% | 0.93% | ||||
Debt | ||||||
Debt current | 1,873 | 1,622 | ||||
Long-term debt | 4,006 | 5,815 | ||||
Deferred revenue | ||||||
Other long-term liabilities | 236 | 161 | ||||
Net debt | (90,460) | (17,105) | ||||
Cash flow | ||||||
Cash from operating activities | (33,275) | (41,683) | ||||
CAPEX | (7) | (8) | ||||
Cash from investing activities | 55,777 | 23,692 | ||||
Cash from financing activities | 49,140 | (241) | ||||
FCF | (101,206) | (46,530) | ||||
Balance | ||||||
Cash | 96,339 | 79,077 | ||||
Long term investments | (54,535) | |||||
Excess cash | 95,835 | 24,542 | ||||
Stockholders' equity | (197,228) | (149,868) | ||||
Invested Capital | 278,582 | 224,691 | ||||
ROIC | ||||||
ROCE | ||||||
EV | ||||||
Common stock shares outstanding | 38,510 | 23,527 | ||||
Price | 2.93 166.99% | 1.10 -75.39% | ||||
Market cap | 112,835 337.03% | 25,819 -75.22% | ||||
EV | 22,375 | 8,714 | ||||
EBITDA | (101,355) | (47,638) | ||||
EV/EBITDA | ||||||
Interest | 483 | 420 | ||||
Interest/NOPBT |